ijms-logo

Journal Browser

Journal Browser

Liver-Gut Axis 3.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2282

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
Interests: leaky gut; endotoxin; nonalcoholic fatty liver disease; alcoholic liver disease; liver fibrosis; Toll-like receptors; probiotics; antibiotics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Gut-derived nutrients and other signals are delivered to the liver via the portal circulation. As the largest immune organ, the liver hosts the entire spectrum of immune-cell repertoire. It has a remarkable capacity to recruit and activate immune cells in response to gut-derived metabolic or pathogen-derived signals. The crosstalk between the gut and the liver is increasingly recognized, strengthened by the parallel rise in liver diseases and gastrointestinal and immune disorders. The gut–liver axis is widely implicated in the pathogenesis of liver disease, including alcoholic liver disease, nonalcoholic fatty liver disease, primary biliary cholangitis, cirrhosis, hepatocellular carcinoma, and acute-on-chronic liver failure. The risk of damage to the liver increases when the intestinal barrier is damaged (“leaky gut”). Intestinal dysbiosis plays an important role in the development of chronic liver disease. The gut–liver axis has evolved from basic research to therapeutic strategies to improve the prognosis of chronic liver diseases. Further research on the gut–liver axis has led to new insights into the pathogenesis of liver disease and therapeutic strategies.

This Special Issue will be dedicated to the “Liver–Gut Axis”; it welcomes submissions, including original papers and reviews, on these widely discussed topics.

Dr. Takemi Akahane
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dysbiosis
  • leaky gut
  • gastrointestinal microbiome
  • endotoxin
  • antibiotics
  • probiotics
  • chronic liver disease
  • liver fibrosis
  • acute-on-chronic liver failure
  • hepatocellular carcinoma

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 3534 KiB  
Article
Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
by Florian Plaza Oñate, Célia Chamignon, Sebastian D. Burz, Nicolas Lapaque, Magali Monnoye, Catherine Philippe, Maxime Bredel, Laurent Chêne, William Farin, Jean-Michel Paillarse, Jérome Boursier, Vlad Ratziu, Pierre-Yves Mousset, Joël Doré, Philippe Gérard and Hervé M. Blottière
Int. J. Mol. Sci. 2023, 24(15), 12232; https://doi.org/10.3390/ijms241512232 - 31 Jul 2023
Cited by 4 | Viewed by 1923
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through [...] Read more.
Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can lead to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observe that compared to healthy controls, Adlercreutzia equolifaciens is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that A. equolifaciens possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of A. equolifaciens and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy for liver diseases. Full article
(This article belongs to the Special Issue Liver-Gut Axis 3.0)
Show Figures

Figure 1

Back to TopTop